



COMPANY OVERVIEW

Aurinia is a late clinical-stage biopharmaceutical company focused on developing and commercializing therapies to change the treatment paradigm for patients impacted by rare autoimmune and inflammatory conditions. Aurinia is advancing voclosporin as a potential best-in-class and first-in-class therapy for the treatment of lupus nephritis (LN) in the U.S. and EU. The company is also conducting a Phase 2 clinical trial of voclosporin in focal segmental glomerulosclerosis (FSGS), a rare kidney disease, and is advancing voclosporin ophthalmic solution (VOS), a topical formulation, for the treatment of dry eye syndrome (DES). Aurinia is actively exploring opportunities to fully realize the untapped potential of novel therapies and create meaningful impact to meet patient needs.

RECENT NEWS

[Aurinia Announces AURORA Phase 3 Clinical Data for Voclosporin in Lupus Nephritis to be Presented at National Kidney Foundation 2020 Spring Clinical Meetings](#)

Mar 18 2020, 6:05 AM EDT

STOCK OVERVIEW

Symbol	AUPH
Exchange	Nasdaq
Market Cap	1.61b
Last Price	\$14.36
52-Week Range	\$3.52 - \$21.93

04/02/2020 04:00 PM EDT

INVESTOR RELATIONS

Glenn Schulman, PharmD, MPH
Senior Vice President, Corporate
Communications and Investor Relations
IR@auriniapharma.com

MANAGEMENT TEAM

Peter Greenleaf
Chief Executive Officer, Director

Dennis Bourgeault
Chief Financial Officer

Max Colao
Chief Commercial Officer

Max Donley, MBA
Executive Vice President, Internal Operations
and Strategy

Erik Eglite, D.P.M., J.D., M.B.A.
Senior Vice President, General Counsel &
Chief Corporate Compliance Officer

Robert Huizinga, Ph.D., R.N., CNeph(C)
Executive Vice President, Corporate
Development

Michael Martin
Chief Operating Officer

Neil Solomons, M.D.
Chief Medical Officer

AURINIA PHARMACEUTICALS INC.

#1203-4464 Markham Street
Victoria, BC V8Z 7X8
Canada

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.